Last reviewed · How we verify
Anti-CD20 Targeting agent — Competitive Intelligence Brief
discontinued
Days 1,8,15, and 22 of the first 28-day cycle and then on Day 1 of subsequent 21-day cycles. The ant
Oncology
Live · refreshed every 30 min
Target snapshot
Anti-CD20 Targeting agent (anti-cd20-targeting-agent) — Pfizer Inc.. Days 1,8,15, and 22 of the first 28-day cycle and then on Day 1 of subsequent 21-day cycles. The ant
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Anti-CD20 Targeting agent TARGET | anti-cd20-targeting-agent | Pfizer Inc. | discontinued | Days 1,8,15, and 22 of the first 28-day cycle and then on Day 1 of subsequent 21-day cycles. The ant |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Days 1,8,15, and 22 of the first 28-day cycle and then on Day 1 of subsequent 21-day cycles. The ant class)
- Pfizer Inc. · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Anti-CD20 Targeting agent CI watch — RSS
- Anti-CD20 Targeting agent CI watch — Atom
- Anti-CD20 Targeting agent CI watch — JSON
- Anti-CD20 Targeting agent alone — RSS
- Whole Days 1,8,15, and 22 of the first 28-day cycle and then on Day 1 of subsequent 21-day cycles. The ant class — RSS
Cite this brief
Drug Landscape (2026). Anti-CD20 Targeting agent — Competitive Intelligence Brief. https://druglandscape.com/ci/anti-cd20-targeting-agent. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab